MedTech device company Creo Medical Group plc has reported a positive set of half-year results.

Creo, based in Chepstow, Wales, enables minimally invasive surgical endoscopy for pre-cancer and cancer patients.

For the six months ended 30th June 2025, revenues were up 40% to £2.2m, while underlying operating costs reduced by 24% to £9.1m. Profit before tax was £16.1m – compared to a loss of £14.8m in the prior year – after it sold 51% of Creo Medical Europe to Micro-Tech in the period.

It has signed a strategic partnership agreement with Micro-Tech.